SpinDiag raises 1,6 Mio seed-capital

Dominique Kosse, Dr. Daniel Mark, Dr. Oliver Strohmeier, Dr. Frank Schwemmer, Dr. Gregor Czilwik und Dr. Mark Keller. Quelle: SpinDiag


The Freiburg-based startup SpinDiag GmbH recently closed a 1.6 Mio. EUR seed-round with three private investors. The team developed a revolutionary point-of-care screening system for testing patients for antibiotic-resistant bacteria at their admission to hospitals and almost instantly so. The seed-capital will make it feasible to bring SpinDiag’s system from its current laboratory environment to first tests in hospitals. “Testing in hospitals will not only be an important milestone for the subsequent market approval of our first product in the following financing rounds, but will demonstrate our potential for bringing infectious disease testing in general to the point of care”, says Dr. Daniel Mark, co-founder and CEO of SpinDiag. The worldwide market for point-of-care testing of infectious diseases is estimated by Grand View Research to be 5.4 billion USD in 2017. SpinDiag will address this market with a revolutionary technology: a fast, broad and affordable system so easy to use that nurses can test patients on the spot.

The problem of patients getting infected by other patients in hospitals with bacteria is increasingly appalling. In hospitals worldwide, about one in 25 patients is infected and thousands of them die as a result each year. “Hospitals are lacking an efficient workflow for handling risk patients. Our system will reduce the time of today’s testing-methods from 2-3 days to 30 minutes, thus obtaining the crucial information: whether a patient puts other patients at risk or not” explains Dr. Mark Keller, co-founder and Chief Product Officer at SpinDiag. He adds: “It is not just about bringing the results to the doctor in a short time, but also to cover all relevant antibiotic resistance and this at an affordable price. We will be the first to bring such a fast, broad and affordable screening to the market and this in an extremely easy to use format for operation by nurses on the ward.”

SpinDiag’s team spent years of research and development at Hahn-Schickard to generate the basic technology for their product: an internationally patented centrifugal microfluidic platform. “The platform-characteristic of our product enables a very powerful product pipeline for the point-of-care testing of infectious diseases such as respiratory tract infections, sepsis and tuberculosis”, Dr. Oliver Strohmeier, co-founder and CTO at SpinDiag points out.

Read the whole press release @ the website of SpinDiag